Home / Therapies / GLP-1 Agonist Therapy Center (page 10)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

Could Glucagon-like Peptide-1 (GLP-1) Agonists Be Delivered Intranasally?

Possibility of non-subcutaneous administration could increase patient compliance….  GLP-1 agonists are effective therapeutic options for treating diabetes. While their effectiveness has been established, compliance with these medications may be limited in some patients due to their subcutaneous route of administration and gastrointestinal adverse effects. In a recent prospective, double-blind, placebo-controlled …

Read More »

GLP-1 Agonist Interaction with Insulin-Induced Hypoglycemia

A study shows GLP-1 agonists slow the acceleration of gastric emptying that occurs as a result of insulin-induced hypoglycemia…. Glucagon-like peptide 1 (GLP-1) receptor agonists are used as monotherapy, secondary therapy with other oral agents, and in combination with basal insulin for management of type 2 diabetes. Though they are …

Read More »

Alternative GLP-1 Delivery Systems

Although glucagon-like peptide-1 (GLP-1) is highly biologically active following intravenous or subcutaneous injection, a non-injectable alternative for activating GLP-1 receptor signaling would clearly be desirable. Studies by Gutniak, Ahren and colleagues in Sweden have shown that GLP-1 formulated in buccal tablets is absorbed into the circulation and lowers blood glucose …

Read More »

Mechanisms and Receptors Controlling Intestinal GLP-1 Secretion, Part 2

David Joffe, BSPharm, CDE  Brittany Davis, Pharm D Candidate, Presbyterian College School of Pharmacy The molecular mechanisms linking fatty acids to GLP-1 secretion from gut endocrine cells remain incompletely understood. Hirasawa and colleagues have identified a GPCR, designated GPR120 that serves as a receptor for fatty acids on gut endocrine cells. …

Read More »

GLP-1 Serum Levels Associated with Coronary Artherosclerosis

Prior reports of GLP-1 vasoprotective effects may not be valid…. Prior reports have shown that GLP-1 concentrations are associated with anti-inflammatory and atheroprotective effects which extend to cardioprotection during acute myocardial infarction. In the body, GLP-1 binds to its receptors on pancreatic beta-cells leading to glucose dependent insulin release. Studies …

Read More »

IV Versus SubQ for GLP-1 Drugs

How to unlock GLP-1 drugs’ full glucose-lowering potential…. The current subcutaneous delivery method of GLP-1 agonist drugs for patients with type 2 diabetes may not be the most effective. According to Michael Nauchk, MD, intravenously administered infusions of GLP-1 resulted in normalization of blood glucose without gastrointestinal upset, while subcutaneous …

Read More »